Ulcerative Colitis: Epidemiology Forecast to 2026 – Update

2019-04-30
Price :
Published : Apr-2019
No. of Pages : 64

Ulcerative Colitis: Epidemiology Forecast to 2026 – Update

Summary

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by long-lasting inflammation and ulcers (sores) in the lining of the colon. UC is limited to the colon and has less frequent complications.

GlobalData’s epidemiological forecast for the diagnosed incidence, diagnosed prevalence, undiagnosed prevalence, and total prevalence of UC in the 7MM is supported by nationally representative, country-specific studies published in peer-reviewed journals of national healthcare databases and registries. In addition, to improve the comparability of the forecast diagnosed incident and diagnosed prevalent cases of UC across markets, GlobalData epidemiologists used sources that provided uniform diagnostic criteria for these subcategories.

In the 7MM, the diagnosed incident cases of UC are expected to increase from 94,303 cases in 2016 to 108,428 cases in 2026, at an Annual Growth Rate (AGR) of 1.5%. The US will have the highest number of diagnosed incident cases of UC over the forecast period, while Spain will have the lowest. In the 7MM, the diagnosed prevalent cases of UC are expected to increase from 1,737,130 cases in 2016 to 1,867,305 cases in 2026, at an AGR of 0.75%. The US will have the highest number of diagnosed prevalent cases of UC over the forecast period, while Spain will have the lowest.

This Update includes revised severity segmentation section in the report and reorganization of severity segmentations in the model.

Scope

– The Ulcerative Colitis (UC) Epidemiology Forecast Report and Epidemiology Forecast Model provide an overview of the risk factors and global trends of UC in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– This report also includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, undiagnosed prevalent cases, and total prevalent cases (both diagnosed and undiagnosed) of UC, segmented by sex and age (starting at ages 0-9 years and ending at ages 80 years and older) in these markets. The diagnosed incident cases are further segmented by stage at diagnosis and severity grading. The diagnosed prevalent cases are further segmented by severity grading. Additionally, autoimmune comorbidities, colectomy due to failure of medical management, and mortality due to complications of UC among the diagnosed prevalent cases of UC are also included in this analysis. Furthermore, the report includes diagnosed incident cases and diagnosed prevalent cases of indeterminate colitis (IC) for both sexes and all ages in the 7MM.
– The Ulcerative Colitis epidemiology forecast report and model were written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
– The Epidemiology Forecast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

– The Ulcerative Colitis (UC) Epidemiology Forecast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global UC market.
– Quantify patient populations in the global UC market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for UC therapeutics in each of the markets covered.
Understand magnitude of UC population by severity, stage at diagnosis, comorbidities, and other clinically relevant segmentations.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Colitis Global Clinical Trials Review, H1, 2019

Colitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Colitis Global Clinical Trials Review, H1, 2019" provides an overview of Colitis clinical trials scenario. This report provides top line data relating to the clinical trials on Colitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated fro......
$2500

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Degenerative Scoliosis Global Clinical Trials Review, H1, 2019" provides an overview of Degenerative Scoliosis clinical trials scenario. This report provides top line data relating to the clinical trials on Degenerative Scoliosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Conjunctivitis Global Clinical Trials Review, H1, 2019

Conjunctivitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Conjunctivitis Global Clinical Trials Review, H1, 2019" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Churg-Strauss Syndrome Global Clinical Trials Review, H1, 2019

Churg-Strauss Syndrome Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Churg-Strauss Syndrome Global Clinical Trials Review, H1, 2019" provides an overview of Churg-Strauss Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Churg-Strauss Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H1, 2019" provides an overview of Cutaneous B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Cutaneous B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Colon Cancer Global Clinical Trials Review, H1, 2019

Colon Cancer Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Colon Cancer Global Clinical Trials Review, H1, 2019" provides an overview of Colon Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Colon Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy